Onena Medicines
Company Details
Status: Private
Employees: 1-10
Location:
Basel, Switzerland
Type:
sample
Technology:
sample
sample
sample
sample
About: Onena Medicines is a biopharmaceutical company with a pipeline of first-in-class antibody medicines to treat recurrent and metastatic cancers and selected rare diseases. Onena’s drugs neutralize a new class of secreted ancient growth factors, conserved across species, called Dual SMAD Inhibiting Proteins (DSIPs), that program cancer cells to grow and resist chemotherapy. Blocking DSIPs, as demonstrated in-vivo by Onena, simultaneously reactivates physiological TGF-β and BMP signaling and elicits cellular reprogramming, resulting in cancer cells accepting environmental cell death signals from BMPs and Activins. Onena has developed a proprietary AI-centric antibody drug discovery platform that rapidly generates anti-DSIP neutralizing antibodies, even when no crystal structure of the antigen is available. OMED-101, Onena’s anti-LEFTY1/2 lead candidate antibody, has demonstrated broad efficacy against breast, colorectal and brain cancers without observable toxicities in preclinical models. Through its unique platform, Onena Medicines has discovered several DSIPs and aims to advance multiple neutralizing DSIP antibody drugs into clinical development in the next three years.
Unlock access to company contacts, hot leads, and drug pipelines.
Log in or create a free account now!
Onena Medicines | Active clinical trials on ClinicalTrials.gov
Active Clinical Trials Count | 0
No Active Trials Found On ClinicalTrials.gov.